These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31980477)

  • 1. Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.
    Podestà MA; Ruggiero B; Remuzzi G; Ruggenenti P
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31980477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
    Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.
    Podestà MA; Gennarini A; Portalupi V; Rota S; Alessio MG; Remuzzi G; Ruggenenti P
    Nephron; 2020; 144(1):30-35. PubMed ID: 31336376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
    Boyer-Suavet S; Andreani M; Lateb M; Savenkoff B; Brglez V; Benzaken S; Bernard G; Nachman PH; Esnault V; Seitz-Polski B
    Front Immunol; 2019; 10():3069. PubMed ID: 31998325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
    Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
    BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of PLA
    Schmidt T; Schulze M; Harendza S; Hoxha E
    J Nephrol; 2021 Apr; 34(2):603-606. PubMed ID: 33026632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection.
    Li X; Song D; Hao Y; Ren M; Guo Y; Zhao H; Wang Y; Tang L
    Sci Rep; 2024 Sep; 14(1):20981. PubMed ID: 39251782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of Patients With Refractory PLA
    Klomjit N; Fervenza FC; Zand L
    Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
    Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
    Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
    Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
    Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
    N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.
    Doyle AJ; Stubbs MJ; Lester W; Thomas W; Westwood JP; Thomas M; Percy C; Prasannan N; Scully M
    Br J Haematol; 2022 Jul; 198(2):391-396. PubMed ID: 35430727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
    Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
    Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.
    Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM
    BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.